Partial nephrectomy for the treatment of translocation renal cell carcinoma
WANG Jujian1, GU Liangyou2, CHENWenzheng2, AI Qing2, CHENG Qiang2, LI Hongzhao2, ZHANG Xu2
1 Department of Urology, Lingshui County People's Hospital of Hainan Province, Lingshui 572400, China;
2 Department of urology, The First Medical Center of Chinese PLA General Hospital
Abstract：Objective： To investigate the outcomes of patients with translocation renal cell carcinoma (RCC) treated with partial nephrectomy. Methods： Our institutional review board-approved kidney cancer database was searched for patients who underwent partial nephrectomy between Jan. 2012 and Dec. 2015 for a pathologically confirmed translocation RCC. We described the demographic, clinical, pathological, and follow-up data for this series of patients. Results： Between Jan. 2012 and Dec. 2015, 3077 patients with RCC were treated at our institution with a partial or radical nephrectomy. In total, 20 (0.5%) patients were diagnosed as a translocation RCC, and 7 (0.2%) of them underwent partial nephrectomy. Of these 7 patients, one was male, six were female, four had a left-side tumor, three had a right-side tumor. The median age was 44 (15-51) years, and the median clinical tumor maximum diameter was 2.8 (1.3-5.6) cm. Six patients received retroperitoneal laparoscopic partial nephrectomy, and one patient received robot-assisted laparoscopic partial nephrectomy. The median operative time was 120 (66-170) min, the median estimated blood loss was 50 (20-200) mL, and the median warm ischemia time was 26 (20-34) min. Pathological results showed that all patients achieved negative margin, no perirenal or sinus fat invasion was identified, and positive lymph node was identified in one patient. The median hospital stay was 15 (9-19) days. During a median follow-up of 42.0 (31.6-61.5) months, all patients were alive without evidence of disease. Conclusions： According to our experience, partial nephrectomy for patients with small translocation RCCs can achieve satisfactory outcomes.
[1] DE JONG B, OOSTERHUIS JW, IDENBURG VJ, et al.Cytogenetics of 12 cases of renal adenocarcinoma. Cancer Genet Cytogenet, 1988,30(1):53-61.
[2] DAVIS IJ, HSI BL, ARROYO JD, et al.Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11) (p21;q13) chromosome translocation. Proc Natl Acad Sci U S A, 2003,100(10):6051-6056.
[3] SRIGLEY JR, DELAHUNT B, EBLE JN, et al.The international society of urological pathology (ISUP) Vancouver classification of renal neoplasia. Am J Surg Pathol, 2013,37(10):1469-1489.
[4] MALOUF GG, CAMPARO P, MOLINIÉ V, et al.Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors. J Urol, 2011,185(1):24-29.
[5] KLATTE T.Renal cell carcinoma associated with transcription factor E3 expression and Xp11. 2 translocation: incidence, characteristics, and prognosis. Am J Clin Pathol, 2012,137(5):761-768.
[6] GELLER JI, ARGANI P, ADENIRAN A, et al.Translocation renal cell carcinoma - Lack of negative impact due to lymph node spread. Cancer, 2008,112(7):1607-1616.
[7] MIR MC, TRILLA E, TORRES IMD,et al.Altered transcription factor E3 expression in unclassified adult renal cell carcinoma indicates adverse pathological features and poor outcome. BJU Int, 2011,108(2 Pt 2),E71-E76.
[8] KURODA N, TANAKA A, SASAKI N, et al.Review of renal carcinoma with t(6;11) (p21;q12) with focus on clinical and pathobiological aspects. Histol Histopathol, 2013,28(6):685-690.
[9] ZHANG X, LI HZ, MA X, et al.Retroperitoneal laparoscopic nephron-sparing surgery for renal tumors: Report of 32 cases. Urology, 2005,65(6):1080-1084.
[10] WHITE MA, HABER GP, AUTORINO RA, et al.Outcomes of robotic partial nephrectomy for renal masses with nephrometry score of ≥ 7. Urology, 2011,77(4):809-813.
[11] ARGANI P, OLGAC S, TICKOO SK, et al.Xp11 translocation renal cell carcinoma in adults: Expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol, 2007,31(8):1149-1160.
[12] ARGANI P, YONESCU R, MORSBERGER L, et al.Molecular confirmation of t(6;11) (p21;q12) renal cell carcinoma in archival paraffin-embedded material using a break-apart TFEB FISH assay expands its clinicopathologic spectrum. Am J Surg Pathol, 2012,36(10):1516-1526.
[13] GREEN WM, YONESCU R, MORSBERGER L, et al.Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service. Am J Surg Pathol, 2013,37(8):1150-1163.
[14] LJUNGBERG B, COWAN NC, HANBURY DC, et al.EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol, 2010,58(3):398-406.
[15] LEVEY AS, STEVENS LA, SCHMID CH, et al.A new equation to estimate glomerular filtration rate. Ann Intern Med, 2009,150(9):604-612.
[16] GU L, MA X, LI H, et al.Comparison of oncologic outcomes between partial and radical nephrectomy for localized renal cell carcinoma: A systematic review and meta-analysis. Surg Oncol, 2016,25(4):385-393.
[17] LJUNGBERG B, BENSALAH K, CANFIELD S, et al.EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol, 2015,67(5):913-924.
[18] CAMPBELL S, UZZO RG, ALLAF ME, et al.Renal mass and localized renal cancer: AUA guideline. J Urol, 2017,198(3):520-529.
[19] BAMBURY RM, BATTLEY JE, MCCARTHY A, et al.Translocation renal cell carcinomas: an evolving entity and a member of the microphthalmia transcription factor-associated family of tumors. Clin Genitourin Cancer, 2013,11(3):357-361.
[20] GORIN MA, BALL MW, PIERORAZIO PM, et al.Partial nephrectomy for the treatment of translocation renal cell carcinoma. Clin Genitourin Cancer, 2015,13(3):e199-e201.
[21] TELLINI R, ANTONELLI A, TARDANICO R, et al.Positive surgical margins predict progression-free survival after nephron-sparing surgery for renal cell carcinoma: results from a single center cohort of 459 cases with a minimum follow-up of 5 years. Clin Genitourin Cancer, 2019,17(1):e26-e31.
